Erin Medoff

Current Trials

• A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)

  HIC ID2000033381RoleSub InvestigatorPrimary Completion Date12/31/2023

  Recruiting Participants

  Leukemia

• BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination With Conventional Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

  HIC ID2000028858RoleSub InvestigatorPrimary Completion Date07/31/2024

  Recruiting Participants

  Leukemia

• A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia

  HIC ID2000023819RoleSub InvestigatorPrimary Completion Date12/31/2028

  Recruiting ParticipantsGenderBothAge18+ years

  Leukemia

• Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

  HIC ID2000024356RoleSub InvestigatorPrimary Completion Date12/31/2023

  Recruiting Participants

  Leukemia

• The National Myelodysplastic Syndromes Natural History Study

  HIC ID1607018080RoleSub InvestigatorPrimary Completion Date01/31/2025

  Recruiting ParticipantsGenderBothAge18+ years

  Leukemia